A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Endometrial Cancer|Solid Tumor, Unspecified, Adult|Colorectal Cancer
Interventions: DRUG: Fruquintinib|DRUG: Tislelizumab
Sponsor: Hutchison Medipharma Limited
Collaborators: BeiGene